Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.67 |
| ▸ | CDK4 | P11802 | 6/20 | 0.47 |
| ▸ | CCND1 | P24385 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274782 | 0.90 | NR1H4 (0.71) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL279155 | 0.86 | NR1H4 (0.71) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL274147 | 0.86 | NR1H4 (0.68) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL274682 | 0.84 | NR1H4 (0.80) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL29881430 | 0.84 | NR1H4 (0.73) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL273500 | 0.84 | NR1H4 (0.73) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL274730 | 0.83 | NR1H4 (0.72) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL275416 | 0.83 | NR1H4 (0.69) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL274804 | 0.82 | NR1H4 (0.76) | NR1H4CDK4CCND1POLBABCB1 | |
| SCHEMBL275299 | 0.82 | NR1H4 (0.73) | NR1H4CDK4CCND1POLBABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | NR1H4 75/4885CDK4 4142/4885CCND1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.